Skip to main content

07-19-2018 | Dapagliflozin | Article

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial

Methieu C et al. Diabetes Care 2018: dc180623. doi: 10.2337/dc18-0623

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics